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Abstract
Aims/hypothesis Recent evidence links the soluble uroki-
nase plasminogen activator receptor (suPAR), a stable bio-
marker of systemic immune activation, to several chronic
diseases, including type 2 diabetes. suPAR is also associated
with adiposity and smoking. We hypothesised that this
biomarker would be linked to incident type 2 diabetes in
individuals with impaired glucose regulation and that this
association would be modified by smoking and body weight
status.
Methods The study included 1,933 participants with im-
paired glucose regulation, who were drawn from the Danish
arm of the Anglo–Danish–Dutch Study of Intensive Treat-
ment in People with Screen-Detected Diabetes in Primary
Care (ADDITION) and for whom data on suPAR, BMI
and smoking were available. Logistic regression analysis
was used to estimate the odds for incident type 2 diabetes
per twofold increase in suPAR levels. Interactions between
both smoking and body weight status and suPAR were
tested.
Results During a 3-year follow-up (599 incident diabetes
cases), there was a 48% overall increase in the odds of
developing type 2 diabetes per twofold increase in
suPAR (p=0.006). This association was modified by
body weight status in overweight, but not in obese in-
dividuals (OR 2.36, 95% CI 1.48, 3.76 in overweight
group), and by smoking status (OR 2.05, 95% CI 1.20,
3.51 in non-smokers). After adjustment for other diabetes
risk factors, the association between suPAR and type 2
diabetes was attenuated in the whole sample and among
non-smokers, but remained robust among overweight
participants.
Conclusions/interpretation suPAR may be a good novel
biomarker for systemic sub-clinical inflammation and im-
mune activation linked to incident type 2 diabetes risk in
overweight individuals and non-smokers. The observed
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interactions with adiposity and smoking should be inves-
tigated further.
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Abbreviations
ADDITION Anglo–Danish–Dutch Study of Intensive
Treatment in People with Screen-Detected
Diabetes in Primary Care
IFG Impaired fasting glycaemia
IGT Impaired glucose tolerance
suPAR Soluble urokinase plasminogen activator
receptor
uPAR Urokinase plasminogen activator receptor
Introduction
Systemic sub-clinical inflammation and immune activation
have been implicated in the pathogenesis of type 2 diabetes
[1]. Although the exact causal mechanisms are yet to be
determined, inflammatory biomarkers may improve predic-
tion of type 2 diabetes and thus enable early detection,
intervention and disease prevention.
The urokinase plasminogen activator receptor (uPAR),
which is present in several types of cell, plays a role in
numerous physiological pathways mainly involving im-
mune activation, e.g. the plasminogen activating pathway,
the modulation of cell adhesion, migration and proliferation,
and tissue remodelling and systemic inflammation [2–4].
uPAR is cleaved and released from cells in response to in-
flammatory stimulation, generating soluble uPAR (suPAR),
which can hence be regarded as a pro-inflammatory marker,
thus providing an interesting candidate risk biomarker for type
2 diabetes. A few studies have shown that, after adjustment for
conventional risk factors, increased levels of suPAR in the
general population are associated with an increased risk of
death from all causes, as well as increased risk of several
chronic diseases, including cancer, cardiovascular disease
and type 2 diabetes [5–7].
Existing evidence also suggests that suPAR levels are
strongly influenced by adiposity [8] and smoking [5]. How-
ever, no evidence exists on the role of body weight status
and smoking as effect-modifying factors in the association
between suPAR and type 2 diabetes, especially among high-
risk individuals.
We aimed to answer the following questions: (1) is
suPAR associated with incident type 2 diabetes in people
at high risk? and (2) is this association modified by body
weight and smoking status?
Methods
Setting and population The study population was drawn
from the Danish arm (DK) of the Anglo–Danish–Dutch
Study of Intensive Treatment in People with Screen-
Detected Diabetes in Primary Care (ADDITION), which
evaluated a systematic screening for people at high risk of
type 2 diabetes conducted among all listed patients aged 40
to 69 years in the 175 participating Danish practices [9].
Blood samples collected at baseline screening (2001 to
2006) were used. Details on the original ADDITION re-
cruitment strategy can be found elsewhere [9]. Of the people
who completed the risk score questionnaire (n=134,016,
response rate 82%), those who had a high risk score (n=
28,041) underwent a step-wise clinical assessment compris-
ing the following: determination of random blood glucose
and HbA1c, and measurement of fasting blood glucose and
an OGTT. The aim was to identify cases of undiagnosed
type 2 diabetes, as well as impaired fasting glycaemia (IFG)
and impaired glucose tolerance (IGT). Of those thus
assessed, 1,933 participants had impaired glucose regulation
(isolated IFG, isolated IGTor combined IFG and IGT), as well
as valid data on suPAR and the potential confounders/effect-
modifiers of interest, and were thus included in the current
analysis.
Diabetes ascertainment The incidence of type 2 diabetes
was ascertained by an OGTT at 1 and 3 years of follow-
up, in combination with regular reports on glucose measure-
ments at GP surgeries up to December 2008.
suPAR assessment suPAR levels were measured in baseline
serum samples using a kit (suPARnostic ELISA; ViroGates,
Birkerød, Denmark).
Statistical analysis The association between log2-
transformed suPAR levels at baseline and incident type 2
diabetes was assessed using logistic regression in a sex-
and age-adjusted model, and in a multivariate-adjusted
model (BMI, waist circumference, systolic blood pressure,
plasma triacylglycerol, HDL-cholesterol, smoking status).
Departure from linearity was assessed by including a
quadratic and cubic term in the model, and by performing
a likelihood ratio test (p>0.30 for all). Analyses were
stratified by body weight status based on BMI (lean,
overweight, obese according to the WHO 1999 definition
[10]) and by smoking status (never/occasional, ex, current),
and interactions were tested using the likelihood ratio
test.
Ethics Informed consent was obtained from all participants
prior to initiation of the study. The study was approved by
the local Ethics Committee and the reported investigations
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were carried out in accordance with the principles of the
Declaration of Helsinki as revised in 2000.
Results
Baseline mean suPAR levels were higher: in (1) women than
in men; (2) among individuals with isolated IGT and com-
bined IFG and IGT compared with those with isolated IFG;
(3) in obese individuals compared with the overweight and
lean; and (4) in current and past smokers compared with
occasional and never-smokers (Table 1).
During a 3-year follow-up, 599 cases of incident type 2
diabetes were identified. Adjusting for age and sex, there was
a 48% overall increase in the odds of developing type 2
diabetes per twofold increase in baseline suPAR level (p=
0.006) (Table 2). We found strong evidence for an interaction
effect between body weight status and suPAR on incident type
2 diabetes (p=0.003), while the suPAR × smoking interaction
was marginally non-significant (p=0.076). The association
between suPAR and incident type 2 diabetes was only appa-
rent in overweight (BMI 25 to <30 kg/m2) participants (OR
2.36, 95% CI 1.48, 3.76 per twofold increase in suPAR levels)
and in non-smokers (OR 2.05, 95% CI 1.20, 3.51). Additional
adjustment for waist circumference, systolic blood pressure,
blood lipids and smoking status attenuated the overall associa-
tion between suPAR and type 2 diabetes. After these adjust-
ments, the association in the non-smoking group was reduced
to marginally non-significant (OR 1.65, 95% CI 0.95, 2.89),
but the association in the overweight group remained robust
(OR 2.14, 95% CI 1.31, 3.51). After repeating the analysis
while stratifying by quintiles of BMI instead of the WHO
classification, the odds of type 2 diabetes increased substan-
tially by log2-suPAR above a BMI of 28 kg/m2, with a drop
occurring at BMI >30 kg/m2. In cross-classification stratified
analysis, the association between suPAR and incident type 2
diabetes was particularly high in participants who were over-
weight and non-smokers (n=261) (OR 5.15, 95% CI 1.92,
13.78). It should be noted that given a mean of 3.36 ng/ml and
standard deviation of 1.16 in our sample, a twofold increase in
suPAR levels represents a relatively big increase (i.e. from the
∼10th to the ~90th percentile of the distribution).
Discussion
Soluble uPAR, a pro-inflammatory biomarker that is elevat-
ed in several infectious diseases, has previously been found
to be linked to increased risk of cancer, cardiovascular
disease and type 2 diabetes [5, 7]. Here, we show that, in a
sample of Danish middle-aged individuals at high risk of
diabetes, higher suPAR levels are linked to higher risk of
type 2 diabetes in non-smokers and overweight participants.
It should be noted here that although we use the word ‘risk’
in our interpretation, the ORs presented are expected to be
larger than the corresponding relative risks, given the high
incidence of type 2 diabetes in our study (~30%).
Although this study was conducted in a highly selected
population (participants with impaired glucose regulation,
including somewhat healthier obese participants and
Table 1 Association between
suPAR concentrations at
baseline and participant
characteristics in 1,933
participants at high risk of
diabetes in the ADDITION
study DK
aMedian (interquartile range)
Characteristic n suPAR (ng/ml)a p value for association
Sex
Men 978 3.05 (2.54, 3.68)
Women 955 3.28 (2.80, 3.91) <0.001
Glucose regulation status
Isolated IFG 800 3.08 (2.55, 3.71)
Isolated IGT 652 3.20 (2.75, 3.88)
IFG and IGT combined 481 3.25 (2.80, 3.82) 0.001
Body weight status
Lean (BMI <25 kg/m2) 341 3.08 (2.58, 3.87)
Overweight (BMI 25 to <30 kg/m2) 806 3.10 (2.54, 3.68)
Obese (BMI ≥30 kg/m2) 786 3.26 (2.82, 3.87) <0.001
Physical activity (n=1,878)
Not active 1,529 3.39 (2.79, 4.08)
Active 349 3.17 (2.67, 3.81) 0.21
Smoking status
Non-smokers 657 2.98 (2.56, 3.45)
Occasional smokers 53 2.94 (2.47, 3.47)
Ex-smokers 691 3.11 (2.58, 3.69)
Current smokers 532 3.60 (3.03, 4.42) <0.001
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unhealthier lean participants due to inclusion by design), our
findings are in agreement with previous evidence indicating
that suPAR levels are strongly associated with body weight
and smoking status. A discrepancy with previous evidence
is the non-linear association between body weight status
and suPAR, which can be explained by the much higher
prevalence of smoking in the lean group of our sample
(data not shown).
Our results show that the association between suPAR and
incident type 2 diabetes is stronger in the overweight par-
ticipants and in non-smokers. In an attempt to disentangle
the effect-modifying roles of body weight and smoking
status, we found that the association between suPAR and
type 2 diabetes was even stronger in participants who were
overweight and non-smokers, indicating that both factors
independently modify this association.
An interaction between suPAR and body weight status in
relation to type 2 diabetes is plausible, given that adiposity
is associated with an unhealthier metabolic profile, and thus
sub-clinical inflammation (of which suPAR is a marker)
may constitute an additional pathophysiological burden,
further increasing the risk of type 2 diabetes. The ‘metabol-
ically healthy obese’ phenotype [11] of our participants (i.e.
non-diabetic despite being obese) may also be resistant to
the pathophysiological burden of systemic inflammation,
providing a possible explanation of the association found
here between suPAR levels and incident type 2 diabetes in
overweight, but not in obese individuals.
With regard to smoking, similar findings indicating that
suPAR is a better pro-inflammatory biomarker among non-
smokers than among smokers were reported in the Danish
MONICA10 cohort study [7]. This proves that, despite the
strong linear association between smoking and suPAR, this
biomarker is not in the causal pathway between smoking and
type 2 diabetes, and may instead represent a genuine pro-
inflammatory pathway in the pathophysiology of the disease.
The exact pathophysiological mechanisms linking
suPAR, and more generally sub-clinical inflammation to
type 2 diabetes are still unclear. It is believed that suPAR
is produced in sites of inflammation by activated neutro-
phils, which contribute to the recruitment of monocytes to
these sites [4], leading to immune activation and under
certain conditions systemic sub-clinical inflammation and
atherosclerosis, independently of other known inflammatory
biomarkers such as C-reactive protein [8]. From the current
results, as well as from previous studies, it is clear that
smoking and body weight status influence this pro-
inflammatory biomarker.
In conclusion, we provide evidence that suPAR may be a
novel pro-inflammatory risk biomarker for progression to
type 2 diabetes in overweight and non-smoking individuals
at high risk of the disease. This interaction is in agreement
with previous studies, but still needs to be further examined,
before it can be used in models for type 2 diabetes prediction.
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OR (95% CI)
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covariatesa OR (95% CI)
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